Parkinson's Disease Clinical Trial Pipeline Boom As 150+ Companies Are In The Race For Better Treatments Delveinsight. The ...

Background Pancreatic ductal adenocarcinoma (PDAC) is largely refractory to immune checkpoint blockade, owing to its ...

What comes after trastuzumab deruxtecan?

Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced the initiation of the Phase III clinical trial for Rentosertib, its ...

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study ...

Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistically significant durable ...

These results support darovasertib plus Xalkori as a potential new standard of care if approved for HLA A*02:01-negative metastatic uveal melanoma.

A new study suggests that higher blood levels of the amino acid tyrosine may be linked to a slightly shorter lifespan, especially in men. But before you toss your protein shake, there’s a major caveat ...

Rare cancer expert Taran Gujral, PhD, cares more about what a cancer drug can do than what it is designed to do. His lab at Fred Hutch Cancer Center investigates a promising target for cancer drugs — ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...

A large genetic analysis suggests that one amino acid linked to protein metabolism could influence how long we live, with potential sex-specific effects that challenge assumptions about diet and ...